Gene therapy for acute renal failure

Contributions to Nephrology

Volumn 159, Issue , 2008, Pages 96-108

  Torras, J ^a   Cruzado, J ^a   Herrero Fresneda, I ^a   Grinyo, J ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1;

ACUTE KIDNEY FAILURE; APOPTOSIS; GENE THERAPY; GENETIC TRANSFECTION; GENETICS; HUMAN; METHODOLOGY; PROTEIN SYNTHESIS; REPERFUSION INJURY; REVIEW;

APOPTOSIS; GENE THERAPY; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; KIDNEY FAILURE, ACUTE; NF-KAPPA B; OLIGONUCLEOTIDES, ANTISENSE; PROTEIN BIOSYNTHESIS; REPERFUSION INJURY; TRANSFECTION;

EID: 48549090819     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000125614     Document Type: Review

References (59)

1. Thadhani R, Pascual M, Bonventre JV: Acute renal failure. N Engl J Med 1996;334:1448-1460.
2. Rabb H, O'Meara YM, Maderna P, Coleman P, Brady HR: Leukocytes, cell adhesion molecules and ischemic acute renal failure. Kidney Int 1997;51:1463-1468.
3. Riera M, Torras J, Herrero I, Valles J, Paubert-Braquet M, Cruzado JM, Alsina J, Grinyo JM: Neutrophils Accentuate Renal Cold Ischemia-Reperfusion Injury. Dose-Dependent Protective Effect of a Platelet-Activating Factor Receptor Antagonist. J Pharmacol Exp Ther 1997;280:786-794.
4. Sheridan AM, Bonventre JV: Cell biology and molecular mechanisms of injury in ischemic acute renal failure. Curr Opin Nephrol Hypertens 2000;9:427-434.
5. Enyu I, Yoshitsugu T, Masayuki M, Yoshitaka I: Gene therapy in renal diseases. Kidney Int 2004;6:1551-1555.
6. Zhu N, Liggitt D, Liu Y, Debs R: Systemic gene expression after intravenous DNA delivery into adult mice. Science 1993;261:209-211.
7. Madry H, Reszka R, Bohlender J, Wagner J: Efficacy of cationic liposome-mediated gene transfer to mesangial cells in vitro and in vivo. J Mol Med 2001;79:184-189.
8. Gojo S, Cooper DK, Iacomini J, LeGuern C: Gene therapy and transplantation. Transplantation 2000;69:1995-1999.
9. Sorgi FL, Bhattacharya S, Huang L: Protamine sulfate enhances lipid-mediated gene transfer. Gene Ther 1997;4:961-968.
10. Morishita R, Gibbons GH, Horiuchi M, Nakajima M, Ellison KE, Lee W, Kaneda Y, Ogihara T, Dzau VJ: Molecular delivery system for antisense oligonucleotides: Enhanced effectiveness of antisense oligonucleotides by HVJ-liposome mediated transfer. J Cardiovasc Pharmacol Ther 1997;2:213-222.
11. Cao CC, Ding XQ, Ou ZL, Liu CF, Li P, Wang L, Zhu CF: In vivo transfection of NF-kappaB decoy oligodeoxynucleotides attenuate renal ischemia/reperfusion injury in rats. Kidney Int 2004;65:834-845.
12. Takahashi Y, Geller DA, Gambotto A, Watkins SC, Fung JJ, Murase N: Adenovirus-mediated gene therapy to liver grafts: successful gene transfer by donor pretreatment. Surgery 2000;128:345-352
13. Poston RS, Billingham ME, Pollard J, Hoyt EG, Robbins RC: Effects of increased ICAM-1 on reperfusion injury and chronic graft vascular disease. Ann Thorac Surg 1997;64:1004-1011.
14. Rabb H, Mendiola CC, Saba SR, Dietz JR, Smith CW, Bonventre JV, Ramirez G: Antibodies to ICAM-1 protect kidneys in severe ischemic reperfusion injury. Biochem Biophys Res Commun 1995;211:67-73.
15. Kuus-Reichel K, Grauer LS, Karavodin LM, Knott C, Krusemeier M, Kay NE: Will immunogenicity limit the use, efficacy, and future development of therapeutic monoclonal antibodies. Clin Diagn Immunol 1994;4:365-371.
16. Mirabelli CK, Crooke ST: Antisense oligonucleotides in the context of modern molecular drug discovery and development; in: Antisense research and application. Boca Raton, CRC Press, 1993, pp 7-12.
17. Haller H, Dragun D, Miethke A, Park JK, Weis A, Lippoldt A, Gross V, Luft FC: Antisense oligonucleotides for ICAM-1 attenuate reperfusion injury and renal failure in the rat. Kidney Int 1996;50:473-480.
18. Dragun D, Tullius SG, Park JK, Maasch C, Lukitsch I, Lippoldt A, Gross V, Luft FC, Haller H: ICAM-1 antisense oligodeoxynucleotides prevent reperfusion injury and enhance immediate graft function in renal transplantation. Kidney Int 1998;54:590-602.
19. Bennett CF, Zuckerman JE, Kornbrust D, Sasmor H, Leeds JM, Crooke ST: Pharmacokinetics in mice of a [3H]-labelled phosphorothioate oligonucleotide formulated in the presence and absence of a cationic lipid. J Control Release 1996;41:121-129.
20. Chen W, Bennett CF, Wang ME, Dragun D, Tian L, Stecker K, Clark JH, Kahan BD, Stepkowski SM: Perfusion of kidneys with unformulated 'naked' ICAM-1 antisense oligodeoxynucleotides prevents ischemic/reperfusion injury. Transplantation 1999;68:880-887.
21. Chen W, Langer RM, Janczewska S, Furian L, Geary R, Qu X, Wang M, Verani R, Condon T, Stecker K, Bennett CF, Stepkowski SM: Methoxyethyl-modified ICAM-1 antisense phosphorothiateoligonucleotides inhibit allograft rejection, ischemic-reperfusion injury, and cyclosporine-induced nephrotoxicity. Transplantation 2005;79:401-408.
22. Barnes PJ, Karin M: Nuclear factor-κB: A pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997;336:1066-1071.
23. Guijarro C, Egido J: Transcription factor-kappa B and renal disease. Kidney Int 2001;59:415-424.
24. Cho-Chung YS, Park YG, Lee YN: Oligonucleotides as transcription factor decoys. Curr Opin Mol Ther 1999;1:386-392.
25. Vos IH, Govers R, Grone HJ, Kleij L, Schurink M, De Weger RA, Goldschmeding R, Rabelink TJ: NF-kappaB decoy oligodeoxynucleotides reduce monocyte infiltration in renal allografts. FASEB J 2000;14:815-822.
26. Li B, Li S, Tan Y, Stolz DB, Watkins SC, Block LH, Huang L: Lyophilization of cationic lipidprotamine-DNA (LPD) complexes. J Pharm Sci 2000;89:355-364.
27. Azuma H, Tomita N, Kaneda Y, Koike H, Ogihara T, Katsuoka Y, Morishita R: Transfection of NFkappaB-decoy oligodeoxynucleotides using efficient ultrasound-mediated gene transfer into donor kidneys prolonged survival of rat renal allografts. Gene Ther 2003;10:415-425.
28. Segerer S, Nelson PJ, Schlondorff D: Chemokines, chemokine receptors, and renal disease: From basic science to pathophysiologic and therapeutic studies. J Am Soc Nephrol 2000;11:152-176.
29. Xia M, Hou C, Demong DE, Pollack SR, Pan M, Brackley JA, Jain N, Gerchak C, Singer M, Malaviya R, Matheis M, Olini G, Cavender D, Wachter M: Synthesis, Structure-Activity Relationship and in Vivo Antiinflammatory Efficacy of Substituted Dipiperidines as CCR2 Antagonists. J Med Chem 2007; in press.
30. Furuichi K, Wada T, Iwata Y, Kitagawa K, Kobayashi K, Hashimoto H, Ishiwata Y, Tomosugi N, Mukaida N, Matsushima K, Egashira K, Yokoyama H: Gene therapy expressing amino-terminal truncated monocyte chemoattractant protein-1 prevents renal ischemia-reperfusion injury. J Am Soc Nephrol 2003;14:1066-1071.
31. Lloberas N, Torras J, Herrero-Fresneda I, Cruzado JM, Riera M, Hurtado I, Grinyo JM: Postischemic renal oxidative stress induces an inflammatory response through PAF and oxidized phospholipids: prevention by antioxidant treatment. FASEB J 2002;16:908-910.
32. Chien CT, Lee PH, Chen CF, Ma MC, Lai MK, Hau SM: De novo demonstration and co-localization of free-radical production and apoptosis formation in rat kidney subjected to ischemia-reperfusion. J Am Soc Nephrol 2001;12:973-982.
33. Salahudeen AK, Huang H, Joshi M, Moore NA, Jenkins JK: Involvement of the mitochondrial pathway in cold storage and rewarming-associated apoptosis of human renal proximal tubular cells. Am J Transplant 2003;3:273-280.
34. Li P, Nijhawan D, Budihardjo I, et al: Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 1997;91:479-489.
35. Antonsson B, Montessuit S, Lauper S, Eskes R, Martinou JC: Bax oligomerization is required for channel-forming activity in liposomes and to trigger cytochrome c release from mitochondria. Biochem J 2000;345:271-278.
36. Adams JM, Cory S: The Bcl-2 protein family arbiters of cell survival. Science 1998;281:1322-1326.
37. Israels LG, Israels ED: Apoptosis. Stem Cells 1999;17:306-313.
38. Zhao H, Yenari MA, Cheng D, Sapolsky RM, Steinberg GK: Bcl-2 over-expression protects against neuron loss within the ischemic margin following experimental stroke and inhibits cytochrome c translocation and caspase-3 activity. J Neurochem 2003;85:1026-1036.
39. Chiang-Ting C, Tzu-Ching C, Ching-Yi T, Song-Kuen S, Ming-Kuen L: Adenovirus-mediated bcl-2 gene transfer inhibits renal ischemia/reperfusion induced tubular oxidative stress and apoptosis. Am J Transplant 2005;5:1194-1203.
40. Zheng X, Feng B, Chen G, Zhang X, Li M, Sun H, Liu W, Vladau C, Liu R, Jevnikar AM, Garcia B, Zhong R, Min WP: Preventing renal ischemia-reperfusion injury using small interfering RNA by targeting complement 3 gene. Am J Transplant 2006;6:2099-2108.
41. Ichim TE, Li M, Qian H, Popov IA, Rycerz K, Zheng X, White D, Zhong R, Min WP: RNA interference: a potent tool for gene-specific therapeutics. Am J Transplant 2004;4:1227-1236.
42. Zender L, Hutker S, Liedtke C, Tillmann HL, Zender S, Mundt B, Waltemathe M, Gosling T, Flemming P, Malek NP, Trautwein C, Manns MP, Kuhnel F, Kubicka S: Caspase 8 small interfering RNA prevents acute liver failure in mice. Proc Natl Acad Sci USA 2003;100:7797-7802.
43. Zheng X, Zhang X, Sun H, Feng B, Li M, Chen G, Vladau C, Chen D, Suzuki M, Min L, Liu W, Zhong R, Garcia B, Jevnikar A, Min WP: Protection of renal ischemia injury using combination gene silencing of complement 3 and caspase 3 genes. Transplantation 2006;82:1781-1786.
44. Vargas GA, Hoeflich A, Jehle PM: Hepatocyte growth factor in renal failure: promise and reality. Kidney Int 2000;57:1426-1436.
45. Matsumoto K, Mizuno S, Nakamura T: Hepatocyte growth factor in renal regeneration, renal disease and potential therapeutics. Curr Opin Nephrol Hypertens 2000;9:395-402.
46. Herrero-Fresneda I, Torras J, Franquesa M, Vidal A, Cruzado JM, Lloberas N, Fillat C, Grinyó JM: HGF gene therapy attenuates renal allograft scarring by preventing the profibrotic inflammatoryinduced mechanisms. Kidney Int 2006;70:265-274.
47. Cruzado JM, Lloberas N, Torras J, Riera M, Fillat C, Herrero-Fresneda I, Aran JM, Alperovich G, Vidal A, Grinyó JM: Regression of advanced diabetic nephropathy by hepatocyte growth factor gene therapy in rats. Diabetes 2004;53:1119-1127.
48. Kawaida K, Matsumoto K, Shimazu H, Nakamura T: Hepatocyte growth factor prevents acute renal failure and accelerates renal regeneration in mice. Proc Natl Acad Sci USA 1994;91:4357-4361.
49. Riera M, Chillon M, Aran JM, Cruzado JM, Torras J, Grinyó JM, Fillat C: Intramuscular SP1017-formulated DNA electrotransfer enhances transgene expression and distributes hHGF to different rat tissues. J Gene Med 2004;6:111-118.
50. Franquesa M, Alperovich G, Herrero-Fresneda I, Lloberas N, Bolaños N, Fillat C, Rama I, Cruzado JM, Grinyó JM, Torras J: Direct electrotransfer of hHGF gene into kidney ameliorates ischemic acute renal failure. Gene Ther 2005;12:1551-1558.
51. Arthur LG, Schwartz MZ, Kuenzler KA, Birbe R: Hepatocyte growth factor treatment ameliorates diarrhoea and bowel inflammation in a rat model of inflammatory bowel disease. J Pediatr Surg 2004;39:139-143.
52. Makondo K, Kimura K, Kitamura T, Yamaji D, Dong Jung B, Shibata H, Saito M: Hepatocyte growth factor/scatter factor suppresses TNF-α-induced E-selectin expression in human umbilical vein endothelial cells. Biochim Biophys Acta 2004;1644:9-15.
53. Humes HD: Cell therapy: leveraging nature's therapeutic potential. J Am Soc Nephrol 2003;14:2211-2213.
54. Gomez-Navarro J, Contreras JL, Arafat W, Jiang XL, Krisky D, Oligino T, Marconi P, Hubbard B, Glorioso JC, Curiel DT, Thomas JM: Genetically modified CD34+ cells as cellular vehicles for gene delivery into areas of angiogenesis in a rhesus model. Gene Ther 2000;7:43-52.
55. Springer ML, Hortelano G, Bouley DM, Wong J, Kraft PE, Blau HM: Induction of angiogenesis by implantation of encapsulated primary myoblasts expressing vascular endothelial growth factor. J Gene Med 2000;2:279-288.
56. Humes HD, Szczypka MS: Advances in cell therapy for renal failure. Transpl Immunol 2004;12:219-227.
57. Issa N, Messer J, Paganini EP: Renal assist device and treatment of sepsis-induced acute kidney injury in intensive care units. Contrib Nephrol 2007;156:419-427.
58. Morigi M, Benigni A, Remuzzi G, Imberti B: The regenerative potential of stem cells in acute renal failure. Cell Transplant 2006;15(suppl 1):S111-S117.
59. Bussolati B, Camussi G: Stem cells in acute kidney injury. Contrib Nephrol 2007;156:250-256.